What is oral ecnoglutide studying for overweight or obesity?

Oral ecnoglutide is being studied to evaluate its safety, how the body absorbs and responds to it, and its effects on weight management in adults with overweight or obesity. Researchers aim to understand these aspects to inform potential treatments. The study is sponsored by Hangzhou Sciwind Biosciences Co., Ltd.

Who may be eligible for this overweight or obesity clinical trial?

Adults aged 18 to 65 with a BMI between 24.0 and 35.0 kg/m2 and body weight over 60 kg for males or 50 kg for females may be eligible. Participants should have stable body weight with less than 5% change in the last 3 months and no major endocrine or cardiovascular diseases. Please review eligibility criteria for more details.

Is there any cost to participate in this overweight or obesity clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses and other costs may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 1

Phase 2

Age: 18Years - 65Years

All Genders

Healthy Volunteers

ID07243171

A Randomized, Double-blind Phase IbIIa Study to Assess Safety and Effects of Oral Ecnoglutide Tablets in Chinese Adults With Overweight or Obesity

Led by Hangzhou Sciwind Biosciences Co., Ltd. · Updated on 2026-01-28

Participants Needed

Research Sites

15 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying oral ecnoglutide tablets to understand their safety, tolerability, how the body processes the drug, and its effects in Chinese adults with overweight or obesity. This trial aims to provide information on these tablets for weight management and metabolic health. The study is a Phase IbIIa randomized, double-blind, placebo-controlled trial sponsored by Hangzhou Sciwind Biosciences Co., Ltd.

CONDITIONS

Brief Title

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Who Can Participate

Age: 18Years - 65Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

BMI between 24.0 and 35.0 kg/m2 at the time of consent
Body weight over 60.0 kg for males, over 50.0 kg for females
Self-reported body weight change less than 5% within 3 months prior to consent

You will not qualify if you...

Overweight or obesity caused by endocrine disorders like Cushing's syndrome
Other significant endocrine disorders such as hyperthyroidism, hypothyroidism, thyroid nodules (TI-RADS class 3 or higher), thyroid cancer, or personal/family history of type 2 multiple endocrine tumor syndrome (MEN2)
Cardiovascular or cerebrovascular diseases with clinical significance within 6 months before screening, including acute stroke, acute coronary syndrome, heart failure, or arrhythmia
Severe gastrointestinal diseases such as inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, diabetic gastroparesis, diabetic diarrhea, or clinical gastric emptying abnormalities
History of major gastrointestinal surgery (except cholecystectomy or appendectomy), metabolic surgery, or planned major surgery during the study
HbA1c equal to or above 6.5%, fasting blood glucose equal to or above 7.0 mmol/L, or OGTT 2-hour blood glucose equal to or above 11.1 mmol/L at screening
Clinical laboratory test results with clinical significance

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Randomized, Double-blind Phase IbIIa Study to Assess Safety and Effects of Oral Ecnoglutide Tablets in Chinese Adults With Overweight or Obesity

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria